Sarah Fredriksson and her company Aqilion in Helsingborg were looking for a molecule with very specific properties to develop a treatment for the inflammatory disease eosinophilic esophagitis. What she was looking for, she found on the other side of the Øresund, at one of Denmark’s larger pharmaceutical companies.
Southern Swedish company Aqilion develops drug for eosinophilic esophagitis
When Aqilion began developing a drug for eosinophilic esophagitis, the molecule was classified as an orphan drug. But the prevalence of the disease now appears to be increasing. “We needed a molecule that is extremely selective,” said the company’s CEO, Sarah Fredriksson, during a meeting last week.
Advertisement
BREAKING